Management ChangeJun 25, 2026, 07:11 AM
Insulet Appoints Jonathan Mazelsky to Board of Directors
AI Summary
Insulet Corporation announced the appointment of Jonathan J. Mazelsky as a Class II director to its Board of Directors, effective July 1, 2026. Mr. Mazelsky brings extensive experience, having served as Executive Chair and former President and CEO of IDEXX Laboratories, Inc., and holding various leadership roles at Philips Healthcare and Agilent Technologies. As a non-employee director, he will receive an initial grant of restricted stock units valued at $216,548 and cash compensation.
Key Highlights
- Jonathan J. Mazelsky appointed as a Class II director, effective July 1, 2026.
- Mr. Mazelsky will stand for election by stockholders at the Company’s 2027 Annual Meeting.
- He will receive an initial grant of restricted stock units with a fair value of $216,548.
- He will also receive cash compensation as per the Company's non-employee director program.
- Mr. Mazelsky is currently Executive Chair of IDEXX Laboratories, Inc. since May 2026.
- He previously served as President and CEO of IDEXX from October 2019 to May 2026.
- He is also a member of the board of directors of Dentsply Sirona Inc.
Price Impact
More from PODD